Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer

Advances in Therapy

Volumn 31, Issue 2, 2014, Pages 234-241

  Schmid, Sebastian Christoph ^a   Geith, Alexander ^a   Böker, Alena ^b   Tauber, Robert ^a   Seitz, Anna Katharina ^a   Kuczyk, Markus ^b   Von Klot, Christoph ^b   Gschwend, Jürgen Erich ^a   Merseburger, Axel Stuart ^b   Retz, Margitta ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Abiraterone; Antihormonal drugs; Castration resistant prostate cancer; Chemotherapy; Docetaxel; Enzalutamide; Metastatic; Oncology; Taxane

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPASSIONATE USE; DRUG SAFETY; FATIGUE; HUMAN; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COMPASSIONATE USE TRIALS; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT FAILURE;

EID: 84899096462     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0092-1     Document Type: Article

References (16)

1. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-5. doi:10.1200/jco.2007.12.4008.
2. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, C-A- Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92. doi:10.1016/S1470-2045(12)70379-0.
3. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, C-A- Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-48. doi:10.1056/NEJMoa1209096.
4. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54. doi:10.1016/s0140-6736(10)61389-x.
5. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010;53(7):2779-96. doi:10.1021/jm901488g.
6. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, NY). 2009;324(5928):787-90. doi:10.1126/science.1168175.
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97. doi:10.1056/NEJMoa1207506.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
9. Institute NC. Common Terminology Criteria for Adverse Events v4.0 NIH publication # 09-7473 (2009).
10. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2013;. doi:10.1016/j.eururo. 2013.06.042.
11. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Antitumour activity of abiraterone acetate against metastatic castrationresistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7):1807-12. doi:10.1093/annonc/mdt136.
12. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castrationresistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802-7. doi:10.1093/annonc/mdt138.
13. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913-25. doi:10.1158/1078-0432.CCR-11-0728.
14. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483-9. doi:10.1158/0008- 5472.CAN-12-3630.
15. Albiges L, Le Moulec S, Loriot Y, Gross Goupil M, De La Motte Rouge T, Guillot A, Fizazi K, Massard C. Response to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate. Ann Oncol. 2012;23(Suppl 9):S294-S318.
16. Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2013;. doi:10.1016/j.eururo.2013.07.022.